Cargando…

Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands

The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not refle...

Descripción completa

Detalles Bibliográficos
Autores principales: Slot, Ed, Hogema, Boris M., Reusken, Chantal B. E. M., Reimerink, Johan H., Molier, Michel, Karregat, Jan H. M., IJlst, Johan, Novotný, Věra M. J., van Lier, René A. W., Zaaijer, Hans L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665189/
https://www.ncbi.nlm.nih.gov/pubmed/33184284
http://dx.doi.org/10.1038/s41467-020-19481-7
_version_ 1783609970357436416
author Slot, Ed
Hogema, Boris M.
Reusken, Chantal B. E. M.
Reimerink, Johan H.
Molier, Michel
Karregat, Jan H. M.
IJlst, Johan
Novotný, Věra M. J.
van Lier, René A. W.
Zaaijer, Hans L.
author_facet Slot, Ed
Hogema, Boris M.
Reusken, Chantal B. E. M.
Reimerink, Johan H.
Molier, Michel
Karregat, Jan H. M.
IJlst, Johan
Novotný, Věra M. J.
van Lier, René A. W.
Zaaijer, Hans L.
author_sort Slot, Ed
collection PubMed
description The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of the Netherlands, which is a highly affected country, using a high-performance immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent throughout age groups (18–72 years), and (iv) antibodies were significantly more often present in younger people (18–30 years). Our study provides vital information on the extent of exposure to SARS-CoV-2 in a country where social distancing is in place.
format Online
Article
Text
id pubmed-7665189
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76651892020-11-17 Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands Slot, Ed Hogema, Boris M. Reusken, Chantal B. E. M. Reimerink, Johan H. Molier, Michel Karregat, Jan H. M. IJlst, Johan Novotný, Věra M. J. van Lier, René A. W. Zaaijer, Hans L. Nat Commun Article The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of the Netherlands, which is a highly affected country, using a high-performance immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent throughout age groups (18–72 years), and (iv) antibodies were significantly more often present in younger people (18–30 years). Our study provides vital information on the extent of exposure to SARS-CoV-2 in a country where social distancing is in place. Nature Publishing Group UK 2020-11-12 /pmc/articles/PMC7665189/ /pubmed/33184284 http://dx.doi.org/10.1038/s41467-020-19481-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Slot, Ed
Hogema, Boris M.
Reusken, Chantal B. E. M.
Reimerink, Johan H.
Molier, Michel
Karregat, Jan H. M.
IJlst, Johan
Novotný, Věra M. J.
van Lier, René A. W.
Zaaijer, Hans L.
Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_full Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_fullStr Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_full_unstemmed Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_short Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_sort low sars-cov-2 seroprevalence in blood donors in the early covid-19 epidemic in the netherlands
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665189/
https://www.ncbi.nlm.nih.gov/pubmed/33184284
http://dx.doi.org/10.1038/s41467-020-19481-7
work_keys_str_mv AT sloted lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT hogemaborism lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT reuskenchantalbem lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT reimerinkjohanh lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT moliermichel lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT karregatjanhm lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT ijlstjohan lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT novotnyveramj lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT vanlierreneaw lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
AT zaaijerhansl lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands